Genetic variation, adipokines, and cardiometabolic disease

Research output: Contribution to journal › Review › Research › peer-review

Standard

Genetic variation, adipokines, and cardiometabolic disease. / Metz, Sophia; Huang, Lam Opal; Kilpeläinen, Tuomas O.

In: Current Opinion in Pharmacology, Vol. 52, 2020, p. 33-39.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Metz, S, Huang, LO & Kilpeläinen, TO 2020, 'Genetic variation, adipokines, and cardiometabolic disease', Current Opinion in Pharmacology, vol. 52, pp. 33-39. https://doi.org/10.1016/j.coph.2020.04.006

APA

Metz, S., Huang, L. O., & Kilpeläinen, T. O. (2020). Genetic variation, adipokines, and cardiometabolic disease. Current Opinion in Pharmacology, 52, 33-39. https://doi.org/10.1016/j.coph.2020.04.006

Vancouver

Metz S, Huang LO, Kilpeläinen TO. Genetic variation, adipokines, and cardiometabolic disease. Current Opinion in Pharmacology. 2020;52:33-39. https://doi.org/10.1016/j.coph.2020.04.006

Author

Metz, Sophia ; Huang, Lam Opal ; Kilpeläinen, Tuomas O. / Genetic variation, adipokines, and cardiometabolic disease. In: Current Opinion in Pharmacology. 2020 ; Vol. 52. pp. 33-39.

Bibtex

@article{524659cb67254cb7b65b6d563fc60a86,
title = "Genetic variation, adipokines, and cardiometabolic disease",
abstract = "Adipokines are adipocyte-secreted cell signalling proteins that travel to distant target organs and tissues, where they regulate a variety of biological actions implicated in cardiometabolic health. In the past decade, genome-wide association studies have identified multiple genetic variants associated with circulating levels of adipokines, providing new instruments for examining the role of adipokines in cardiometabolic pathologies. Currently, there is limited genetic evidence of causal relationships between adipokines and cardiometabolic disease, which is consistent with findings from randomized clinical trials that have thus far shown limited success for adipokine-based treatments in improving cardiometabolic health. Incorporating human genetic data in early phases of target selection is essential for enhancing the success of adipokine-based therapies for cardiometabolic disease.",
author = "Sophia Metz and Huang, {Lam Opal} and Kilpel{\"a}inen, {Tuomas O.}",
year = "2020",
doi = "10.1016/j.coph.2020.04.006",
language = "English",
volume = "52",
pages = "33--39",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier Ltd. * Current Opinion Journals",

}

RIS

TY - JOUR

T1 - Genetic variation, adipokines, and cardiometabolic disease

AU - Metz, Sophia

AU - Huang, Lam Opal

AU - Kilpeläinen, Tuomas O.

PY - 2020

Y1 - 2020

N2 - Adipokines are adipocyte-secreted cell signalling proteins that travel to distant target organs and tissues, where they regulate a variety of biological actions implicated in cardiometabolic health. In the past decade, genome-wide association studies have identified multiple genetic variants associated with circulating levels of adipokines, providing new instruments for examining the role of adipokines in cardiometabolic pathologies. Currently, there is limited genetic evidence of causal relationships between adipokines and cardiometabolic disease, which is consistent with findings from randomized clinical trials that have thus far shown limited success for adipokine-based treatments in improving cardiometabolic health. Incorporating human genetic data in early phases of target selection is essential for enhancing the success of adipokine-based therapies for cardiometabolic disease.

AB - Adipokines are adipocyte-secreted cell signalling proteins that travel to distant target organs and tissues, where they regulate a variety of biological actions implicated in cardiometabolic health. In the past decade, genome-wide association studies have identified multiple genetic variants associated with circulating levels of adipokines, providing new instruments for examining the role of adipokines in cardiometabolic pathologies. Currently, there is limited genetic evidence of causal relationships between adipokines and cardiometabolic disease, which is consistent with findings from randomized clinical trials that have thus far shown limited success for adipokine-based treatments in improving cardiometabolic health. Incorporating human genetic data in early phases of target selection is essential for enhancing the success of adipokine-based therapies for cardiometabolic disease.

U2 - 10.1016/j.coph.2020.04.006

DO - 10.1016/j.coph.2020.04.006

M3 - Review

C2 - 32480034

AN - SCOPUS:85085525919

VL - 52

SP - 33

EP - 39

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -

ID: 242518523